Plenty of studies have revealed that LOXL2 participated in tumor progression, metastasis, poor prognosis and chemoradiotherapy resistance in varied cancers, e.g., lung cancer, breast cancer, pancreatic cancer and colorectal cancer (77–80). This evidence concerns the gene LOXL2 and colorectal cancer.